Published in final edited form as:
Bioorg Med Chem Lett. 2007 August 1; 17(15): 4316–4319. doi:10.1016/j.bmcl.2007.05.026.

Anti-AIDS Agents 72. Bioisosteres (7-carbon-DCKs) of the potent anti-HIV lead DCK

Yang Wang[a], **Shao-Xu Huang**[a], **Peng Xia**[a,*], **Yi Xia**[b], **Zheng-Yu Yang**[b], **Nicole Kilgore**[c], **Susan L. Morris-Natschke**[b], and **Kuo-Hsiung Lee**[b,*]

a *Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 200032, China*

b *Natural Products Research Laboratories, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360, USA*

c *Panacos Pharmaceuticals, Inc., 209 Perry Parkway, Suite 7, Gaithersburg, MD 20877, USA*

Abstract

Three 9,10-di-*O*-(−)-camphanoyl–7,8,9,10-tetrahydro-benzo[*h*]chromen-2-one (7-carbon-DCK) analogs (**3a–c**) were synthesized and evaluated for inhibition of HIV-1 replication in H9 lymphocytes. All three new carbon bioisosteres of the anti-HIV lead DCK showed anti-HIV activity. Compound **3a** had an EC_{50} value of 0.068 μM, which was comparable to that of DCK in the same assay. The preliminary results indicated that 7-carbon-DCK analogs merit attention as potential HIV-1 inhibitors for further development into clinical trials candidates.

Keywords

Anti-HIV activity; DCK; Bioisostere

3′,4′-Di-*O*-(−)-camphanoyl-(+)-*cis*-khellactone (DCK, **1**) demonstrated extremely potent inhibitory activity against HIV-1 replication in H9 lymphocytic cells with an EC_{50} value of 2.56×10^{-4} μM and a therapeutic index (TI) of 1.37×10^5 in our prior research.[1] In subsequent structural modification studies, numerous DCK derivatives were synthesized and at least 20 DCK analogs have shown promising inhibitory activity against HIV-1 replication in H9 lymphocytes.[2] Among them, 3-methyl, 4-methyl, and 5-methyl substituted DCKs were much more potent than DCK and AZT in the same assay with EC_{50} and TI values ranging from 5.25×10^{-5} to 2.39×10^{-7} μM and 2.15×10^6 to 3.97×10^8, respectively.[3] In addition, a preliminary mechanistic study showed that 3-hydroxymethyl-4-methyl DCK inhibits HIV reverse transcriptase (RT) *via* a different mechanism of action from those of current clinical anti-HIV/AIDS drugs.[4] It was also found that DCK analogs are strongly synergistic with approved drugs such as AZT and act at a point in the virus life cycle immediately following the target for AZT and nevirapine.[4] In our recent research on structural modification of 4-methyl DCK (**2**), the ring oxygen atom in the A or C ring of DCK was replaced by a sulfur atom, and these sulfur-containing analogs also exhibited potent inhibitory effects on HIV-1 replication in H9 lymphocytes.[5,6] Moreover, *gem*-dimethyl substitution at the 8-position was found to be

*Corresponding authors. Tel.: +86 21 54237563 (P.X.); tel.: +1 919 962 0066; fax: +1 919 966 3893 (K.-H.L.); e-mail addresses: E-mail: pxia@shmu.edu.cn; E-mail: khlee@unc.edu.

preferable to larger alkyl substituents or hydrogen atoms.[7] In a continuing effort to identify the pharmacophores in this class of potent anti-HIV agents, we designed a new series of DCK analogs, namely 7-carbon-DCK derivatives (**3a–c**). In these compounds, a methylene group replaces the oxygen in the C ring of DCK. Thus, these analogs are bioisosteres of DCK, and the effect of the 7-oxygen atom on the anti-HIV activity of DCK-type compounds can be further explored. In addition, to help determine the possible impact of the 8,8-dimethyl groups, both unsubstituted (**3a–b**) and dimethylated (**3c**) analogs were prepared. Herein, we report the synthesis of compounds **3a**–**c** and their preliminary anti-HIV bioassay results (Fig. 1).

The synthesis of **3a–b** was accomplished by a 7-step sequence, as illustrated in Scheme 1. The key intermediates 7,8-dihydro-benzo[*h*]chromen-2-one (**10a**) and its 4-methyl analog (**10b**) were prepared according to the procedure reported in our prior work.[8] Sharpless asymmetric dihydroxylation (AD) of **10a** and **10b** afforded dihydroxy derivatives **11a** and **11b** in moderate yield (45–49%).[9] Finally, 7-carbon-DCK analogs **3a** and **3b** were obtained in 62% and 82% yields, respectively, by acylation of **11a** and **11b** with (*S*)-(−)-camphanic chloride in CH_2Cl_2 at room temperature with pyridine as acid scavenger.

As shown in Scheme 2, the preparation of **3c** followed a slightly different synthetic route with 5-methoxy-1-tetralone (**12**) as starting material. Dimethylation of **12** with CH_3I in the presence of *t*-BuOK afforded 2,2-dimethyl-5-methoxy-1-tetralone (**13**) in 91% yield.[10] Reduction of dimethylated tetralone **13** with H_2 catalyzed with 10% Pd-C gave 1,2,3,4-tetrahydro-5-methoxy-2,2-dimethylnaphthalene (**14**) quantitatively.[11] Demethylation of **14** with BBr_3 resulted in the formation of phenol derivative **15** in 98% yield.[11] The remaining synthetic steps followed those detailed above for **3a–b** from phenol **5**. The target compound **3c** was thus obtained in an overall yield of 5% *via* a six-step reaction sequence starting from **15**.

The anti-HIV activities of compounds **3a–c** were evaluated in H9 lymphocytes, with AZT as the reference compound. The bioassay data are shown in Table 1 and indicated that all three compounds inhibited HIV replication and had reasonable therapeutic index (TI) values. Compounds **3a** and **3b** had significant EC_{50} values of 0.068 and 0.083 μM, respectively. Thus, the presence of the C-4 methyl in these 7-carbon DCK analogs did not lead to increased potency, in contrast to results with DCK and 4-methyl DCK. Although an absence of *gem*-dimethylation was detrimental in the 7-oxy DCK series,[7] it was hard to make a definitive conclusion in the 7-carbon DCK series (comparison of **3c** with **3b**) due to solubility problems with **3c**. However, the 7-carbon analog **3b** was more potent and had a higher TI than the corresponding demethylated 7-oxy DCK derivative, 2′,2′-dihydro-4-methyl DCK (EC_{50} = 6.9 μM, TI > 6).[7] Compound **3b** was also more potent against HIV replication but was more cytotoxic than the analogous 7-thio analog (EC_{50} = 0.141 μM, TI = 1,110).[6]

Further structural modification and biological screening are in progress as these promising bioassay results demonstrate that 7-carbon-DCK analogs merit attention as potential HIV-1 inhibitors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by grants from the National Natural Science Foundation of China (No. 20272010 and 20672022) awarded to P. Xia and Y. Wang, respectively, a research grant (20020246069) for Ph.D. program from the National Education Administration of China awarded to P. Xia, and Grant AI-33066 from the National Institute of Allergies and Infectious Diseases awarded to K. H. Lee.

References and notes

1. Huang L, Kashiwada Y, Cosentino LM, Fan S, Chen CH, McPhail AT, Fujioka T, Mihashi K, Lee KH. J Med Chem 1994;37:3947. [PubMed: 7525962]
2. Yu D, Suzuki M, Xie L, Morris-Natschke SL, Lee KH. Med Res Rev 2003;23:322. [PubMed: 12647313]
3. Xie L, Takeuchi Y, Cosentino LM, Lee KH. J Med Chem 1999;42:2662. [PubMed: 10411486]
4. Xie L, Yu D, Wild C, Allaway G, Turpin J, Smith PC, Lee KH. J Med Chem 2004;47:756. [PubMed: 14736256]
5. Xia P, Yin ZJ, Chen Y, Zhang Q, Zhang BN, Xia Y, Yang ZY, Kilgore N, Wild C, Morris-Natschke SL, Lee KH. Bioorg Med Chem Lett 2004;14:3341. [PubMed: 15149703]
6. Chen Y, Zhang Q, Zhang BN, Xia P, Xia Y, Yang ZY, Kilgore N, Wild C, Morris-Natschke SL, Lee KH. Bioorg Med Chem 2004;12:6383. [PubMed: 15556756]
7. Zhang Q, Chen Y, Xia P, Xia Y, Yang ZY, Yu DL, Morris-Natschke SL, Lee KH. Bioorg Med Chem Lett 2004;14:5855. [PubMed: 15501055]
8. Wang Y, Huang SX, Xia P. Synth Commun 2005;35:3141.
9. Sharpless KB, Amberg W, Bennani YL, Crispino GA, Hartung J, Jeong KS, Kwong HL, Morikawa K, Wang ZM, Xu D, Zhang XL. J Org Chem 1992;57:2768.
10. Gabriel Garcia J, Enas JD, Fronczek FR, VanBrocklin HF. J Org Chem 1994;59:8299.
11. Bayston DJ, Fraser JL, Ashton MR, Baxter AD, Polywka MEC, Moses E. J Org Chem 1998;63:3137.
12. Physical and spectral data for 3a–c: 9,10-Di-*O*-(−)-camphanoyl–7,8,9,10-tetrahydro-benzo[*h*] chromen-2-one (3a) mp 120–122 °C; ^{1}H NMR ($CDCl_3$, 300 MHz) δ0.94–1.13 (m, 18H, camphanoyl CH_3), 1.61–2.56 (m, 10H, 8-H, camphanoyl CH_2), 3.07–3.17 (m, 2H, 7-H), 5.31–5.40 (m, 1H, 9-H), 6.38 (d, *J* = 9.3 Hz, 1H, 3-H), 6.82 (d, *J* = 2.7 Hz, 1H, 10-H), 7.12 (d, *J* = 8.1 Hz, 1H, 6-H), 7.44 (d, *J* = 8.1 Hz, 1H, 5-H), 7.67 (d, *J* = 9.6 Hz, 1H, 4-H). ESI-MS *m/z* (%): 615.25 ($M+Na^+$, 100). HR-MS: calcd for $C_{33}H_{36}O_{10}Na^+$ 615.2201, found 615.2191. 9,10-Di-*O*-(−)-camphanoyl–4-methyl–7,8,9,10-tetrahydro-benzo[*h*]chromen-2-one (3b) mp 159–161 °C; ^{1}H NMR ($CDCl_3$, 300 MHz) δ0.96–1.12 (m, 18H, camphanoyl CH_3), 1.61–2.56 (m, 10H, 8-H, camphanoyl CH_2), 2.42 (s, 3H, 4-CH_3), 3.00–3.20 (m, 2H, 7-H), 5.31–5.38 (m, 1H, 9-H), 6.24 (s, 1H, 3-H), 6.83 (d, *J* = 2.7 Hz, 1H, 10-H), 7.12 (d, *J* = 8.1 Hz, 1H, 6-H), 7.55 (d, *J* = 8.1 Hz, 1H, 5-H). ESI-MS *m/z* (%): 606.30 (M^+, 19). HR-MS: calcd for $C_{34}H_{38}O_{10}Na^+$ 629.2357, found 629.2367. 9,10-Di-*O*-(−)-camphanoyl–4,8,8-trimethyl–7,8,9,10-tetrahydro-benzo[*h*]chromen-2-one (3c) mp 148–150 °C; ^{1}H NMR ($CDCl_3$, 300 MHz) δ0.92–1.30 (m, 24H, camphanoyl CH_3, 8-CH_3), 1.61–1.76 (m, 2H, camphanoyl CH_2), 1.86–1.98 (m, 2H, camphanoyl CH_2), 2.11–2.28 (m, 2H, camphanoyl CH_2), 2.45 (s, 3H, 4-CH_3), 2.50–2.61 (m, 2H, camphanoyl CH_2), 2.82–3.02 (m, 2H, 7-H), 5.35 (d, *J* = 5.1 Hz, 1H, 9-H), 6.25 (s, 1H, 3-H), 6.76 (d, *J* = 5.1 Hz, 1H, 10-H), 7.11 (d, *J* = 8.4 Hz, 1H, 6-H), 7.59 (d, *J* = 8.1 Hz, 1H, 5-H). ESI-MS *m/z* (%): 657.30 ($M+Na^+$, 100). HR-MS: calcd for $C_{36}H_{42}O_{10}Na^+$ 657.2670, found 657.2690.



Figure 1.
Structures of DCK (**1**), 4-methyl DCK (**2**) and 7-carbon-DCK analogs (**3a–c**).



Scheme 1.

Synthesis of **3c**: (i) *t*-BuOK/THF, reflux, 5 h, CH_3I, 0.5 h; (ii) H_2, Pd-C, CH_3SO_3H, HOAc, $CH_3COOC_2H_5$, C_2H_5OH, rt, 36 h; (iii) BBr_3/CH_2Cl_2, −78°C; (iv) $CH_3COCH_2COOC_2H_5$, $POCl_3$, Benzene, reflux, 24 h, 66.0%; (v) CrO_3, HOAc, rt, 30 h, (yield: **17**=39.0%, **18**=19.9%); (vi) $NaBH_4$, CH_3OH, 0.5 h, (yield: 70.3%); (vii) 2% H_2SO_4, 120–130°C, 5 h, (yield: 95.0%); (viii) AD-mix-α ($K_2OsO_4{\cdot}2H_2O$, $K_3Fe(CN)_6$, $(DHQ)_2PHAL$, K_2CO_3), *t*-butanol/H_2O 1:1, $CH_3SO_2NH_2$, rt, 32 h, (yield: 75.5%); (ix) (*S*)-camphanic chloride, Et_3N, DMAP, CH_2Cl_2, rt, 4 h, (yield: 81.2%).



Scheme 2.

Synthesis of **3a–b**: (i) Raney Ni-Al alloy, 1% aq. KOH/water, 90°C, 2 h; (ii) *L*-Malic acid, H_2SO_4, HOAc, 140°C, 6 h (R=H); $CH_3COCH_2COOC_2H_5$, $POCl_3$, 100°C, 18 h (R=CH_3); (iii) CrO_3, HOAc, rt, 3 days; (iv) $NaBH_4$, CH_3OH, 1 h; (v) 2% H_2SO_4, reflux, 6–16 h; (vi) AD-mix-α ($K_2OsO_4{\cdot}2H_2O$, $K_3Fe(CN)_6$, $(DHQ)_2PHAL$, K_2CO_3), *t*-butanol/H_2O 1:1, rt, 2–3 days; (vii) (*S*)-camphanic chloride, pyridine, DMAP, CH_2Cl_2, rt, 24 h.

Table 1

Anti-HIV data of compounds **3a–c** in acutely infected H9 lymphocytes

Compound	IC_{50} (μM)[a]	EC_{50} (μM)[b]	TI[c]
3a	57.2	0.068	841
3b	54.4	0.083	659
3c[d]	>39.4	<0.39	>100
DCK[e]	>16.1	0.049	>328
4-Me DCK[e]	>38.9	0.0059	>6,600
AZT	500	0.0137	36,520

[a] Concentration that inhibits uninfected H9 cell growth by 50%.

[b] Concentration that inhibits viral replication by 50%.

[c] TI = therapeutic index IC_{50}/EC_{50}.

[d] More precise data could not be determined due to solubility problems.

[e] The data for DCK and 4-methyl DCK were cited from Ref. 8. EC_{50} and TI values for DCK and 4-methyl DCK were 2.56×10^{-4} μM, 1.83×10^{-6} μM, and 1.37×10^{5}, 6.89×10^{7}, respectively, in previous screenings, using a different methodology, and publications.[1]